Latest Pathophysiology of multiple sclerosis Stories

Magnetic resonance imaging (MRI) measurements of atrophy in an important area of the brain are an accurate predictor of multiple sclerosis (MS), according to a new study published online in the journal Radiology. According to the researchers, these atrophy measurements offer an improvement over current methods for evaluating patients at risk for MS. MS develops as the body's immune system attacks and damages myelin, the protective layer of fatty tissue that surrounds nerve cells within the...

Magnetic resonance imaging measurements of atrophy in an important area of the brain are an accurate predictor of multiple sclerosis (MS), according to a new study published online Tuesday, April 23, in the journal Radiology. According to the researchers, these atrophy measurements offer an improvement over current methods for evaluating patients at risk for MS. Oak Brook, Ill (PRWEB) April 22, 2013 Magnetic resonance imaging (MRI) measurements of atrophy in an important area of the brain...

Lawrence LeBlond for redOrbit.com - Your Universe Online The painful, debilitating symptoms associated with myelin disorders, such as multiple sclerosis and cerebral palsy, may one day be avoided if new breakthroughs in medical science have anything to say about it. One such breakthrough by a team of scientists at Case Western Reserve School of Medicine (CaseMed) has discovered a technique that directly converts skin cells into a type of brain cells destroyed in patients with these myelin...

Role of cells other than motor neurons much larger than anticipated Johns Hopkins scientists say they have evidence from animal studies that a type of central nervous system cell other than motor neurons plays a fundamental role in the development of amyotrophic lateral sclerosis (ALS), a fatal degenerative disease. The discovery holds promise, they say, for identifying new targets for interrupting the disease's progress. In a study described online in Nature Neuroscience, the...

People with multiple sclerosis (MS) who have cognitive problems, or problems with memory, attention, and concentration, have more damage to areas of the brain involved in cognitive processes than people with MS who do not have cognitive problems, according to a study published in the March 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology. The study used a type of MRI brain scan called diffusion tensor imaging along with regular MRI scans to...

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ -- Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb paralysis), prevented inflammation in the brain and spinal column while also protecting against...

Lawrence LeBlond for redOrbit.com - Your Universe Online Patients with debilitating multiple sclerosis may discover just how fast their nervous system disease is progressing with a new quick and easy test. The test, known as an Optical Coherence Tomography (OCT) scan, takes just a few minutes per eye and can be performed at a general practitioner’s surgery. The finding comes from a test of 164 MS patients measuring the thickness of the lining at the back of the eye. The test was...

GAITHERSBURG, Md., Dec. 18, 2012 /PRNewswire/ -- Molecular diagnostics company DioGenix, Inc. today announced it raised $1.5 million in Series B financing. Existing investors including life sciences fund Nerveda LLC participated in the round to support a prospective, multi-site clinical trial to validate MSPrecise(TM), DioGenix' proprietary next-generation sequencing test for the early identification and diagnosis of multiple sclerosis (MS). In a recently completed study, MSPrecise...

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc., a company developing molecular diagnostics for the early diagnosis and monitoring of immune-mediated neurological diseases, today announced its lead product MSPrecise(TM) outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having multiple sclerosis (MS) by almost two to one with no loss of sensitivity. MSPrecise is a proprietary...

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc. today announced an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise(TM), a proprietary next-generation sequencing assay that measures changes to the...